Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0044
Los Angeles, California, United States
Local Institution - 0081
Riverside, California, United States
Local Institution - 0087
San Francisco, California, United States
Local Institution - 0125
Tampa, Florida, United States
Local Institution - 0056
Hapeville, Georgia, United States
Local Institution - 0023
New Lenox, Illinois, United States
Wichita Urology Group
Wichita, Kansas, United States
Local Institution - 0001
Baltimore, Maryland, United States
Local Institution - 0077
Ann Arbor, Michigan, United States
Local Institution - 0032
Minneapolis, Minnesota, United States
Start Date
August 2, 2018
Primary Completion Date
August 22, 2022
Completion Date
August 24, 2022
Last Updated
June 1, 2023
142
ACTUAL participants
Nivolumab
BIOLOGICAL
BCG
BIOLOGICAL
BMS-986205
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT07222488
NCT05614739
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions